.

Deeper Knowledge, Faster

  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Cerilliant
Moodys
Citi
Cipla
Daiichi Sankyo
Dow
Queensland Health
Boehringer Ingelheim
McKesson

Generated: July 23, 2017

DrugPatentWatch Database Preview

ULTRAVIST 240 Drug Profile

« Back to Dashboard

What is the patent landscape for Ultravist 240, and when can generic versions of Ultravist 240 launch?

Ultravist 240 is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in ULTRAVIST 240 is iopromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iopromide profile page.

Summary for Tradename: ULTRAVIST 240

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list34
Clinical Trials: see list690
Patent Applications: see list895
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ULTRAVIST 240 at DailyMed

Pharmacology for Tradename: ULTRAVIST 240

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
ULTRAVIST 240
iopromide
INJECTABLE;INJECTION020220-003May 10, 1995RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ULTRAVIST 240

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare
ULTRAVIST 240
iopromide
INJECTABLE;INJECTION020220-003May 10, 19954,364,921► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Deloitte
Covington
Moodys
Julphar
US Army
Teva
Harvard Business School
Fish and Richardson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot